Editas Medicine reported a strong financial position, with a cash runway extending into Q2 2027. The company ended Q2 with $179 million in cash, providing sufficient funding to advance EDIT-401 through human proof-of-concept and beyond. Additionally, resources are allocated for discovery work, including the optimization of the hematopoietic stem cell (HSC) program and identifying an additional target by the end of the year.